These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 19366348)

  • 1. Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.
    Fattal E; Barratt G
    Br J Pharmacol; 2009 May; 157(2):179-94. PubMed ID: 19366348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative nanotechnologies for the delivery of oligonucleotides and siRNA.
    Toub N; Malvy C; Fattal E; Couvreur P
    Biomed Pharmacother; 2006 Nov; 60(9):607-20. PubMed ID: 16952435
    [TBL] [Abstract][Full Text] [Related]  

  • 3. State of the art and perspectives for the delivery of antisense oligonucleotides and siRNA by polymeric nanocarriers.
    Fattal E; Bochot A
    Int J Pharm; 2008 Dec; 364(2):237-48. PubMed ID: 18619528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System.
    Mendonça MCP; Kont A; Aburto MR; Cryan JF; O'Driscoll CM
    Mol Pharm; 2021 Apr; 18(4):1491-1506. PubMed ID: 33734715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymer nanocarriers for the delivery of small fragments of nucleic acids: oligonucleotides and siRNA.
    de Martimprey H; Vauthier C; Malvy C; Couvreur P
    Eur J Pharm Biopharm; 2009 Mar; 71(3):490-504. PubMed ID: 18977435
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral delivery of siRNA and antisense oligonucleotides.
    Akhtar S
    J Drug Target; 2009 Aug; 17(7):491-5. PubMed ID: 19530907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biological barriers to therapy with antisense and siRNA oligonucleotides.
    Juliano R; Bauman J; Kang H; Ming X
    Mol Pharm; 2009; 6(3):686-95. PubMed ID: 19397332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dermal/transdermal delivery of small interfering RNA and antisense oligonucleotides- advances and hurdles.
    Ita K
    Biomed Pharmacother; 2017 Mar; 87():311-320. PubMed ID: 28064104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipid conjugated oligonucleotides: a useful strategy for delivery.
    Raouane M; Desmaële D; Urbinati G; Massaad-Massade L; Couvreur P
    Bioconjug Chem; 2012 Jun; 23(6):1091-104. PubMed ID: 22372953
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hyaluronan-based delivery of therapeutic oligonucleotides for treatment of human diseases.
    Ossipov DA
    Expert Opin Drug Deliv; 2019 Jun; 16(6):621-637. PubMed ID: 31072142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA.
    Juliano RL
    Curr Opin Mol Ther; 2005 Apr; 7(2):132-6. PubMed ID: 15844620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymersome delivery of siRNA and antisense oligonucleotides.
    Kim Y; Tewari M; Pajerowski JD; Cai S; Sen S; Williams JH; Sirsi SR; Lutz GJ; Discher DE
    J Control Release; 2009 Mar; 134(2):132-40. PubMed ID: 19084037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular delivery of siRNA and antisense oligonucleotides via receptor-mediated endocytosis.
    Ming X
    Expert Opin Drug Deliv; 2011 Apr; 8(4):435-49. PubMed ID: 21381985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides.
    Juliano R; Alam MR; Dixit V; Kang H
    Nucleic Acids Res; 2008 Jul; 36(12):4158-71. PubMed ID: 18558618
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Click conjugated polymeric immuno-nanoparticles for targeted siRNA and antisense oligonucleotide delivery.
    Chan DP; Deleavey GF; Owen SC; Damha MJ; Shoichet MS
    Biomaterials; 2013 Nov; 34(33):8408-15. PubMed ID: 23932248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting the lung using siRNA and antisense based oligonucleotides.
    Moschos SA; Spinks K; Williams AE; Lindsay MA
    Curr Pharm Des; 2008; 14(34):3620-7. PubMed ID: 19075738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nano and microtechnologies for the delivery of oligonucleotides with gene silencing properties.
    De Rosa G; La Rotonda MI
    Molecules; 2009 Jul; 14(8):2801-23. PubMed ID: 19701125
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery.
    Bochot A; Couvreur P; Fattal E
    Prog Retin Eye Res; 2000 Mar; 19(2):131-47. PubMed ID: 10674705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug delivery system of therapeutic oligonucleotides.
    Asami Y; Yoshioka K; Nishina K; Nagata T; Yokota T
    Drug Discov Ther; 2016; 10(5):256-262. PubMed ID: 27890899
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Central administration of small interfering RNAs in rats: a comparison with antisense oligonucleotides.
    Senn C; Hangartner C; Moes S; Guerini D; Hofbauer KG
    Eur J Pharmacol; 2005 Oct; 522(1-3):30-7. PubMed ID: 16213482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.